QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.

Wenjia ZuoZhonghua WangJun QianXiaopeng MaZhaofeng NiuJianghua OuQinguo MoJing SunXinzheng LiQitang WangYongzhong YaoGuohua YuHongsheng LiDedian ChenHao ZhangCuizhi GengGuangdong QiaoMengmeng ZhaoBaihui ZhangXiaoyan KangJin Zhang Zhimin Shao

Published in: British journal of cancer (2024)

Chinadrugtrials.org CTR20201073; ClinicalTrials.gov NCT04629846.

Keyphrases

phase iii
locally advanced
double blind
open label
rectal cancer
epidermal growth factor receptor
clinical trial
placebo controlled
neoadjuvant chemotherapy
metastatic breast cancer
phase ii
squamous cell carcinoma
phase ii study
radiation therapy
tyrosine kinase
breast cancer cells
combination therapy
young adults